Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2025

Caitlin E. Cox

July 31, 2025

News Daily News

Valve Thrombosis in TTVR Not Uncommon: Meta-analysis

Caitlin E. Cox

June 17, 2025

News Opinion CV Team Dispatch

December 2024 Dispatch for the CV Team

L.A. McKeown

December 20, 2024

News Conference News THT 2024

Debating the Role of T-TEER in the Sickest Patients

Michael O'Riordan

March 05, 2024

News Daily News

Similar Outcomes in Men and Women After Transcatheter Tricuspid Interventions

Michael O'Riordan

April 05, 2023

News Conference News THT 2023

Higher Gradient After Tricuspid TEER Not Harmful at 1 Year: TriValve Registry

Caitlin E. Cox

March 21, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2023

Shelley Wood

March 01, 2023

News Opinion CV Team Dispatch

January 2023 News Roundup

L.A. McKeown

January 16, 2023

News Daily News

ACC’s Valve Staging Tool Reveals Silent Disease is Common in the Elderly

L.A. McKeown

December 22, 2022

News Conference News STS 2022

Bicuspid SAVR Outcomes Meet or Beat Tricuspid in STS Database

L.A. McKeown

February 02, 2022

News Conference News PCR London Valves 2021

Promising Early Results for TriClip in Tricuspid Regurgitation: bRIGHT Registry

Shelley Wood

November 24, 2021

News Opinion CV Team Dispatch

November 2021 News Roundup

L.A. McKeown

November 01, 2021

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

News Daily News

Television Viewing Time Linked to Higher Mortality From Pulmonary Embolism

L.A. McKeown

July 25, 2016

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

Advertisement

What’s Going to Be Hot at TCT 2025

CVD Still the Leading Cause of Death and Disease Globally

TCTMD’s Top 10 Most Popular Stories for July 2025

Valve Thrombosis in TTVR Not Uncommon: Meta-analysis

December 2024 Dispatch for the CV Team

Debating the Role of T-TEER in the Sickest Patients

Similar Outcomes in Men and Women After Transcatheter Tricuspid Interventions

Higher Gradient After Tricuspid TEER Not Harmful at 1 Year: TriValve Registry

TCTMD’s Top 10 Most Popular Stories for February 2023

January 2023 News Roundup

ACC’s Valve Staging Tool Reveals Silent Disease is Common in the Elderly

Bicuspid SAVR Outcomes Meet or Beat Tricuspid in STS Database

Promising Early Results for TriClip in Tricuspid Regurgitation: bRIGHT Registry

November 2021 News Roundup

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Television Viewing Time Linked to Higher Mortality From Pulmonary Embolism

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content